ClinVar Miner

Submissions for variant NM_032043.3(BRIP1):c.2324A>G (p.Asn775Ser)

gnomAD frequency: 0.00003  dbSNP: rs571108955
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000165749 SCV000216492 likely benign Hereditary cancer-predisposing syndrome 2022-09-29 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000656813 SCV000278901 uncertain significance not provided 2023-10-03 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in individuals with breast, ovarian, or other cancers, as well as both cases and unaffected controls in several cancer studies (Lu et al., 2015; Balllinger et al., 2016; Lin et al., 2016; Chan et al., 2018; Terashima et al., 2019; Wang et al., 2019; Momozawa et al., 2019; Okawa et al., 2023); This variant is associated with the following publications: (PMID: 30093976, 26689913, 26824983, 24728327, 25783483, 26580448, 27498913, 32566746, 31666926, 30982232, 11301010, 36243179, 35171259, 31214711, 29929473)
Color Diagnostics, LLC DBA Color Health RCV000165749 SCV000537560 likely benign Hereditary cancer-predisposing syndrome 2019-11-25 criteria provided, single submitter clinical testing
Invitae RCV000475545 SCV000547288 uncertain significance Familial cancer of breast; Fanconi anemia complementation group J 2022-10-26 criteria provided, single submitter clinical testing This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 775 of the BRIP1 protein (p.Asn775Ser). This variant is present in population databases (rs571108955, gnomAD 0.2%). This missense change has been observed in individual(s) with breast cancer, ovarian cancer, sarcoma, stomach cancer, prostate cancer, and neuroblastoma (PMID: 26580448, 26689913, 26824983, 27498913, 30093976, 30982232, 31214711). ClinVar contains an entry for this variant (Variation ID: 133753). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRIP1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Counsyl RCV000663063 SCV000786124 uncertain significance Fanconi anemia complementation group J; Neoplasm of ovary 2018-02-27 criteria provided, single submitter clinical testing
Cancer Genomics Group, Japanese Foundation For Cancer Research RCV001030536 SCV001193532 uncertain significance Hereditary breast ovarian cancer syndrome 2019-05-01 criteria provided, single submitter research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000120397 SCV001361206 uncertain significance not specified 2019-10-10 criteria provided, single submitter clinical testing Variant summary: BRIP1 c.2324A>G (p.Asn775Ser) results in a conservative amino acid change located in the ATP-dependent helicase, C-terminal domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00013 in 251318 control chromosomes, predominantly at a frequency of 0.0017 within the East Asian subpopulation in the gnomAD database. The observed variant frequency within East Asian control individuals in the gnomAD database is approximately 27.2 fold of the estimated maximal expected allele frequency for a pathogenic variant in BRIP1 causing Breast Cancer phenotype (6.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. c.2324A>G has been reported in the literature in individuals affected with breast, ovarian, stomach, and prostate cancers and neuroblastoma without strong evidence of causality (Chan_2018, Lin_2016, Lu_2015, Momozawa_2019, Wang_2019, Zhang_2015). These reports do not provide unequivocal conclusions about association of the variant with Breast Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS- possibly benign.
Genetic Services Laboratory, University of Chicago RCV000120397 SCV002068811 uncertain significance not specified 2018-03-26 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003315735 SCV004019490 likely benign Familial cancer of breast 2023-03-02 criteria provided, single submitter clinical testing This variant is considered likely benign. Homozygosity for this variant has been confirmed in one or more individuals lacking clinical features consistent with gene-specific recessive disease, indicating that this variant is unlikely to be pathogenic.
Baylor Genetics RCV003315735 SCV004214638 uncertain significance Familial cancer of breast 2023-10-22 criteria provided, single submitter clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV003492523 SCV004240394 uncertain significance Breast and/or ovarian cancer 2023-05-25 criteria provided, single submitter clinical testing
ITMI RCV000120397 SCV000084549 not provided not specified 2013-09-19 no assertion provided reference population
True Health Diagnostics RCV000165749 SCV000787965 uncertain significance Hereditary cancer-predisposing syndrome 2018-02-07 no assertion criteria provided clinical testing
Leiden Open Variation Database RCV000120397 SCV001364470 benign not specified 2019-08-13 no assertion criteria provided curation Curator: Arleen D. Auerbach. Submitter to LOVD: Yukihide Momozawa.
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000656813 SCV001551988 uncertain significance not provided no assertion criteria provided clinical testing The BRIP1 p.Asn775Ser variant was identified in 1 of 266 proband chromosomes (frequency: 0.004) from Taiwanes individuals or families with breast cancer (Lin 2016). The variant was also identified in dbSNP (ID: rs571108955) as “With Uncertain significance allele”, ClinVar (4x, uncertain significance), Clinvitae (3x), and was not identified in Cosmic, MutDB, or the Zhejiang Colon Cancer Database. The variant was identified in control databases in 31 of 277046 chromosomes at a frequency of 0.0001 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include African in 1 of 24026 chromosomes (freq: 0.00004) and East Asian in 30 of 18840 chromosomes (freq: 0.002), while not observed in the Other, Latino, European, Ashkenazi Jewish, Finnish, and South Asian populations. The p.Asn775 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact of Serine to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Laboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan University RCV003153386 SCV003843730 likely pathogenic Ovarian cancer 2022-01-01 flagged submission clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.